| Website | regentis.co.il |
| Category | BioTech |
| Phone | +972.4.6265502 |
| info@regentis.co.il | |
| Employees |
| TOTAL | $10M |
| VENTURE FUNDING TOTAL | $10M |
| Series C, 5/12 Royal DSM Medica Venture Partners SCP Vitalife Partners | $10M |
With offices in Or Akiva, Israel and Princeton, NJ, Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary hydrogels for tissue regeneration. The company’s core technology is a iodegradable hydrogel called Gelrin™. It is based on polyethylene glycol diacrylate and denatured fibrinogen originally developed at the Technion University by Dr. Dror Seliktar. The Gelrin hydrogel platform combines the stability and versatility of a synthetic material with the bio-functionality of a natural substance for a range of clinical applications and has undergone extensive preclinical and safety testing over the last few years. The company’s flagship product, GelrinC™, designed for the treatment of articular cartilage lesions, is currently in clinical trials.
